Track 1: Drug Delivery and Pharmacology
Drug Delivery Conferences attains greater global significance as Drug Delivery plays a significant role in the future of pharmaceutical research Novel drug delivery system method by which a drug is delivered can have a significant effect on its efficacy. Conference includes topics like Polymers to enhance drug delivery technology by providing controlled release of therapeutic agents in constant doses over long periods, cyclic dosage, and tunable release of both hydrophilic and hydrophobic drugs. In vitro & in vivo dissolution testing is required to ensure that drug dissolves at a consistent rate from batch to batch of formulated drug product. Improvement of dissolution rate of poorly soluble drugs can be increased by dissolving them in liquid hydrophilic vehicles followed by soaking on highly porous materials. The major part is to deliver an innovative speech on the latest Targeted drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. Pharmacokinetic behavior in drug design and development for safety issues arising either as a result of animal toxicity testing or in the clinical program itself.
There are more than 1400 sustained or controlled release drugs have been approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.
The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of the market share. It is presently valued at $49 billion and is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectable only drugs.
Track 2: Different Routes of Drug Administration
Aimed and specially designed session for young and senior researcher from academic on Novel routes for drug delivery where researcher interested for developing novel routes to minimize side effects for common routes by which a drug is brought into contact with the body session includes different routes of administration like Topical drug delivery via a large range of classes including but not limited to creams, foams, gels, lotions, and ointments. Pulmonary mode of drug delivery system route is gaining much importance in the present day research field as it enables to target the drug delivery directly to lung both for local and systemic treatment. Nasal drug delivery an alternative route restricted to intravenous administration this area has been widely investigated in recent years by academics. Topics like other novel routes wise Vaginal drug delivery covers self-insertion creams, foams, gels, irrigations and tablets, are known to reside in the vaginal cavity. Oral Drug Delivery routes to reaching different parts of the body via the bloodstream. Injectable formulations intended for administration by injection, infusion or implantation into the body.
Track 3: Smart Drug Delivery System
To maximize knowledge of the current researcher on developing drug delivery via smart polymers, Smart Drug Delivery conference themed quality topics on Biodegradable polymers, Dendrimer a versatile polymer in drug delivery are a uniquely architect session to play an important role in the fields of nanotechnology, pharmaceutical and medicinal chemistry.
Major drugs driving growth of the overall smart drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex.
Track 4: Nanotechnologies for Drug Delivery
Nano technologies for Drug Delivery session plays major role in the future of pharmaceutical research In this session, we will go over several of the most important features of nanotechnology that will impact our lives but we will also talk about what nanotechnology itself will be like in the future and Investigator specifically from cancer therapy. Interestingly pharmaceutical sciences are using nanoparticles to reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems themselves may impose risks to the patient.
Nano technology session includes Mesoporous silica nanoparticles targeted cancer treatment, recent breakthroughs in nanoparticle design to demonstrate their high potential as multifunctional drug delivery nanocarriers. Delivery of Nano Particles, Various nanostructures, magnetic nanoparticles. In this review Nano crystals for Drug Delivery, Challenges and advances in nanotechnology to deliver highly efficient therapeutic compounds to patient a future aspect of Nanotechnology has a vast future ahead of it and we are constantly making breakthroughs in this industry every day.
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group. Peptisyntha Inc. And Lonza Inc
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019
Track 5: New Horizons in Vaccine Drug Delivery
Vaccine Drug Delivery is multidisciplinary scientific field that is currently undergoing rapid development. An important component of cancer vaccines is the development of novel vaccine delivery strategies, this session includes Laser technology for Vaccine Delivery, Challenges and opportunities For Vaccine Delivery These advances promise to accelerate the development and testing Jet injectors, micro needles, Needle free drug delivery technology, is an innovative technique to deliver drugs into a person's body without piercing their skin.
Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.
Track 6: Bio therapeutics as Novel Technique in Drug Delivery
Bio therapeutics session is beginning to change for small, medium, and large scale pharmaceutical & biotechnology companies which can manifest from development to manufacturing. Addressing these instabilities is a great challenge, because of the complexity of the bio therapeutics themselves. This session includes Rheological behavior, Pharmaceutical Industry perspectives, Advances in computational modeling for bioavailability, Stability of Pharmaceutical products which are driving crucial research into new vaccines and medicines. The pharmaceutical industry and the public sector are thinking differently than before about how to improve access to medicines and advance research and development for neglected diseases.
Key players profiled in this report include Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc.
The global market for pharmaceutical and biopharmaceutical contract manufacturing, research and packaging was $219.9 billion in 2012. This market is estimated to reach $242.2 billion in 2013 and $374.8 billion by 2018, a five-year compound annual growth rate (CAGR) of 9.1%.
Track 7: Medical Devices for Drug Delivery, Therapy and Surgery
In this session we will focus on devices designed for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of drugs to the system circulation and direct delivery to the central nervous system. Devices that account for specific anatomical and physiological features of the intranasal and pulmonary routes will be featured. Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration. Such devices are used as part of one or more medical treatments.Many in the industry has long felt overly burdened by what they consider to be an unnecessarily complex approval process. Critics claim it impedes innovation and delays the availability of better health care.
To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.
The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.
Track 8: Recent Advances and Breakthrough Research in Drug Delivery Technology
The scope of this session on research in Drug Delivery Technology includes
1. Opportunities and challenges for Drug Delivery Market in the Pharmaceuticals industry
2. Market revenues and forecasts for Drug Delivery Market inthe global pharmaceutical industry from 2009 to 2025.
3. The key geographies including the US, Europe, Japan and Emerging Hotspots such as India, Singapore and China.
4. Technology trends in Drug Delivery Market that shape the industry
5. Qualitative analysis of the market drivers, barriers, future outlook and challenges for the Oral Drug Delivery Market.
6. Analysis of competitive landscape and the leading market players.
Major drugs driving growth of the overall drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, and Peptisyntha Inc.
Track 9: Major challenges and Future Opportunities in Drug Delivery
By focusing on challenges and opportunities in the drug-delivery technology market
There is an increasing demand for effective and, ideally, non-invasive drug-delivery methods. This is especially the case for the biopharmaceutical sector, which has experienced an overwhelming growth due to advances in biotechnology. In 2009, over $12 billion were invested in biologics / biotechnology research and development (R&D), representing a 26% share in the total R&D expenditure. A recent report by the Pharmaceutical Research and Manufacturers of America (PhRMA) states that in 2015 there were 901 biological in development, targeting more than 100 diseases.
Track 10: Global Policy and Business Development of Drug Delivery Technology
The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S. constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% for 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists.
Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery.
Joe Jensen
Steven A Giannos
Simi Gunaseelan
Rajiv Nayar
Laili-Che Rose
Alessandro Grattoni
Russell Burge
Michael O Rourke 
Hussaini Syed Sha Qhattal
Samer-R-Abulateefeh
Xinyuan Chen
Mircea Alexandru Mateescu
Mark-Cresswell
Hidetaka Akita 
Bernard Vrijens
Mitra Mosharraf
Daryl C Drummond
Krishna Polu
